Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1251P - Development of a deep learning algorithm for lung cancer diagnosis using methylation and fragment size profiles of cfDNA

Date

21 Oct 2023

Session

Poster session 14

Topics

Cancer Diagnostics

Tumour Site

Small Cell Lung Cancer;  Non-Small Cell Lung Cancer

Presenters

Jiyoung Huh

Citation

Annals of Oncology (2023) 34 (suppl_2): S711-S731. 10.1016/S0923-7534(23)01942-7

Authors

J. Huh1, M. Kim2, J. Park2, W. Kim2, C. Ki2, E. Cho2, B. Jeong3

Author affiliations

  • 1 Laboratory Medicine, CHA Bundang Medical Center, 13496 - Seongnam/KR
  • 2 Genome Research Center, GC Genome, 16924 - Youngin-si/KR
  • 3 Department Of Medicine, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1251P

Background

Abnormal methylation of cell-free DNA (cfDNA) enables the diagnosis of lung cancer. In this study, we aimed to identify the best methylation marker for distinguishing lung cancer from healthy individuals, and then develop a deep learning algorithm using methylation and fragment size profiles (MFS) of cfDNA in that region.

Methods

We obtained 828 tissue samples from lung cancer patients, 74 adjacent normal tissue samples, and 656 samples of normal whole blood from the TCGA database and generated genome-wide tissue and plasma methylome data from healthy individuals and lung cancer patients using 215 Methylated DNA immunoprecipitation sequencing (MeDIP-Seq) and 24 Enzymatic Methyl-seq (EM-seq). A total of 366 DNA methylation markers were selected based on the methylation profiling of these datasets, and a targeted EM-seq panel was designed on these markers. The panel was used to produce 142 lung cancer samples (stage I: 26%, II: 11%, III: 42%, IV: 11%, unknown: 11%) and 56 healthy samples. MFS was trained on hyper- and hypo-methylated regions using convolutional neural networks. To confirm the limit of detection (LOD), sequencing was performed on diluted samples of healthy and lung cancer cfDNA with different ratios (tumor fractions of 0.1%, 0.5%, and 1%).

Results

We found that the performance was better in hypo-methylated regions than in hyper-methylated regions. The lung cancer detection performance in the test and external sets reached an accuracy of 81.5% (CI: 78.2% to 87.0%) and an AUC of 0.87 (CI: 0.83 to 0.94). At a specificity of 80%, the sensitivity for cancer detection was 77.5% (CI: 67.3% to 99.4%). The sensitivity for Lung Adenocarcinoma and Lung Squamous Cell Carcinoma at 80% specificity was 61.1% (CI: 42.7% to 94.4%) and 85.7% (CI: 71.4% to 100.0%), respectively. With serial dilution results, we detected down to 0.1% tumor fraction with a specificity of 80%.

Conclusions

This study developed and validated a methylation marker and deep learning model that can distinguish between lung cancer patients and healthy individuals using methylation and size information. This approach provides a sensitive and accurate diagnostic tool for lung cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

GC Genome.

Funding

Ministry of Health and Welfare.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.